The HIMALAYA trial, a global Phase III study published in 2023, evaluated the STRIDE regimen, a single high-priming dose of tremelimumab (anti-CTLA-4) plus durvalumab (anti–PD-L1) in patients with unresectable HCC and no prior systemic therapy [38]. Here, CTLA4 is linked to hepatocellular carcinoma.